Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 21, 2006

Cardinal Health Inks Cell Line Development Deal with Wyeth

  • Cardinal Health entered a feasibility agreement with Wyeth to develop cell lines using Cardinal Health’s Gene Product Expression (GPEx®) cell line engineering technology.

    Cardinal Health will use the technology to engineer cell lines that express two undisclosed biopharmaceutical molecules in experiments that will determine if the GPEx approach is a feasible augmentation to Wyeth’s current production methods.

    In addition to enabling rapid cell line development and availability of candidate gene products, the GPEx technology is “well suited for both efficient pilot and large-scale production of antibodies and other therapeutic recombinant proteins,” notes Paul Weiss, Ph.D., president of Cardinal Health’s biopharmaceutical development services center.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »